Terns Pharmaceuticals Bolsters Leadership with Appointment of Seasoned CFO

FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Andrew Gengos as chief financial officer, effective immediately. This strategic move signals Terns' commitment to enhancing its financial leadership and driving growth in its mission to transform patients' lives through innovative medicines.

Andrew Gengos brings over 25 years of experience in finance and corporate strategy in the life sciences industry, making him an ideal fit for Terns' current needs. His extensive background includes serving as the chief financial officer of Athira Pharma, Inc., leading the finance team that took Cyteir Therapeutics public as chief business officer, and holding chief executive officer roles at ImmunoCellular Therapeutics and Neuraltus Pharmaceuticals. Gengos' proven track record of financial leadership and strategic guidance across multiple therapeutic areas, including oncology and neurodegenerative disease, aligns perfectly with Terns' focus on developing treatments for serious diseases.

“I am pleased to be joining Terns as we advance our lead oncology and obesity programs towards compelling clinical readouts later this year,” said Mr. Gengos. “I look forward to working with the talented Terns’ leadership team to build on the Company’s strong financial foundation and drive continued success in bringing new treatment options to patients battling serious diseases, including oncology and obesity.”

Terns Pharmaceuticals' pipeline includes three clinical stage development programs, including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort prioritizing a GIPR antagonist nomination candidate. With Gengos' appointment, Terns is well-positioned to navigate the financial aspects of these critical milestones and capitalize on potential successes.



The appointment of Andrew Gengos as chief financial officer comes at a crucial time for Terns Pharmaceuticals, as the company expects key clinical readouts for its lead oncology and obesity programs later in the year. Gengos' extensive experience and proven track record of financial leadership make him an invaluable addition to Terns' leadership team, poised to drive growth and enhance the company's ability to execute on its strategic goals.

In conclusion, the appointment of Andrew Gengos as chief financial officer at Terns Pharmaceuticals signals the company's commitment to strengthening its financial leadership and driving growth in its mission to develop innovative medicines for serious diseases. With Gengos' extensive experience and proven track record, Terns is well-equipped to navigate the financial aspects of its clinical development programs and capitalize on potential successes. As the company approaches key clinical readouts for its lead oncology and obesity programs, investors can look forward to the strategic guidance and financial expertise that Gengos brings to the table.